ALB and non-small cell lung carcinoma: The aim was to investigate the clinical efficacy of camrelizumab plus albumin-bound paclitaxel as a third- or later-line regimen for advanced NSCLC patients, to provide a novel reference for advanced NSCLC patients’ treatment.